Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1

Blood

Volumn 116, Issue 1, 2010, Pages 113-121

  Meltzer, Mirjam E ^a,b   Lisman, Ton ^a,c   De Groot, Philip G ^a   Meijers, Joost C M ^d   Le Cessie, Saskia ^b   Doggen, Carine J M ^b,e   Rosendaal, Frits R ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; DISEASE ASSOCIATION; ENDOTHELIUM; EUGLOBULIN LYSIS TEST; GENDER; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS; ADOLESCENT; BLOOD; BLOOD CLOTTING TEST; FEMALE; FIBRINOLYSIS; MALE; MIDDLE AGED; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; FEMALE; FIBRINOLYSIS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77955874727     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-267740     Document Type: Article

References (42)

1. Meltzer ME, Lisman T, Doggen CJM, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS MED. 2008;5(5):e97.
2. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102-1105. (Pubitemid 40170881)
3. Guimarães AH, de Bruijne EL, Lisman T, et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol. 2009;145(1):115-120.
4. Meltzer ME, Doggen CJM, de Groot PhG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol. 2009;145(1):121-127.
5. Lisman T, Leebeek FWG, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121(1):131-139. (Pubitemid 32591523)
6. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood. 2004;103(6):2157-2161. (Pubitemid 38326233)
7. Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood. 2006;108(9):3021-3026.
8. Okamoto A, Sakata T, Mannami T, et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. J Thromb Haemost. 2003;1(11):2397-2403.
9. Mellbring G, Dahlgren S, Reiz S, Wiman B. Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. Thromb Res. 1983;32(6):575-584. (Pubitemid 14216155)
10. Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor - relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemost. 1985;54(3):713-716. (Pubitemid 16195325)
11. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95(9):2855-2859. (Pubitemid 30235895)
12. Libourel EJ, Bank I, Meinardi JR, et al. Cosegregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica. 2002;87(10):1068-1073. (Pubitemid 35192219)
13. Eichinger S, Schonauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103(10):3773-3776. (Pubitemid 38596294)
14. Folkeringa N, Coppens M, Veeger NJ, et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost. 2008;100(1):38-44. (Pubitemid 351948743)
15. Folsom AR, Cushman M, Heckbert SR, Rosamond WD, Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol. 2003;56(6):598-603. (Pubitemid 36842919)
16. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med. 1991;151(9):1721-1731.
17. Hartge P, Brinton LA, Rosenthal JF, et al. Random digit dialing in selecting a population-based control group. Am J Epidemiol. 1984;120(6):825-833. (Pubitemid 15216797)
18. Clauss A. Rapid physiological coagulation method in determination of fibrinogen [in German]. Acta Haematol. 1957;17(4):237-246.
19. Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2001;21(4):611-617. (Pubitemid 32323396)
20. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 1996;94(9):2057-2063.
21. Jenkins GR, Seiffert D, Parmer RJ, Miles LA. Regulation of plasminogen gene expression by interleukin-6. Blood. 1997;89(7):2394-2403. (Pubitemid 27143286)
22. Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol. 1994;59(4):233-255. (Pubitemid 24193625)
23. Meltzer ME, Hasstedt SJ, Doggen CJM, et al. Hypofibrinolysis as a risk factor for thrombosis and linkage analysis of clot lysis time in a protein C deficient kindred [abstract]. J Thromb Haemost. 2009;7:162.
24. Undas A, Brozek J, Jankowski M, et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol. 2006;26(6):1397-1404. (Pubitemid 44305388)
25. Mao SJ, Tucci MA. Lipoprotein (a) enhances plasma clot lysis in vitro. FEBS Lett. 1990;267(1):131-134.
26. Declerck PJ, De Mol M, Alessi MC, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988;263(30):15454-15461.
27. Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem. 1980;255(21):10214-10222. (Pubitemid 11214600)
28. Schreiber AD, Kaplan AP, Austen KF. Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest. 1973;52(6):1394-1401.
29. Booth NA. Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12(3):423-433.
30. Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med. 2002;126(11):1376-1381.
31. Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men [published online ahead of print April 22, 2010]. Blood. doi:10.1182/blood-2010- 01-263103.
32. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86(1):324-333. (Pubitemid 32663963)
33. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood. 1989;73(1):185-190.
34. Stalboerger PG, Panetta CJ, Simari RD, Caplice NM. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost. 2001;86(3):923-928. (Pubitemid 32834206)
35. Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med. 1995;126(4):377-384.
36. Pendurthi UR, Ngyuen M, Andrade-Gordon P, Petersen LC, Rao LV. Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol. 2002;22(9):1421-1426.
37. Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271(28):16603-16608. (Pubitemid 26239017)
38. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995;96(5):2534-2538.
39. Hernán MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155(2):176-184. (Pubitemid 34072741)
40. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;152(10):897-907.
41. Van Hylckama Vlieg A, Callas PW, Cushman M, Bertina RM, Rosendaal FR. Inter-relation of coagulation factors and d-dimer levels in healthy individuals. J Thromb Haemost. 2003;1(3):516-522.
42. Juhan-Vague I, Alessi MC, Joly P, et al. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acutephase response. Arteriosclerosis. 1989;9(3):362-367. (Pubitemid 19139871)